Last $25.18 USD
Change Today +0.33 / 1.33%
Volume 208.4K
ABMD On Other Exchanges
As of 5:20 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

abiomed inc (ABMD) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/10/14 - $30.77
52 Week Low
09/27/13 - $18.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ABIOMED INC (ABMD)

Related News

No related news articles were found.

abiomed inc (ABMD) Related Businessweek News

No Related Businessweek News Found

abiomed inc (ABMD) Details

ABIOMED, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. Its products consist of Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP, a micro heart pump; and Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. The company also manufactures and sells the Impella RP, a percutaneous catheter-based axial flow pump; and AB5000 circulatory support system and the BVS 5000 biventricular support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, it offers Symphony, a synchronized minimally invasive implantable cardiac assist device designed to treat chronic patients with moderate heart failure by improving patient hemodynamics; and AbioCor program. The company sells its products through direct sales and clinical support personnel in the United States, Canada, Germany, France, the United Kingdom, and internationally. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.

511 Employees
Last Reported Date: 05/28/14
Founded in 1981

abiomed inc (ABMD) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $519.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $315.9K
Chief Operating Officer
Total Annual Compensation: $341.8K
Vice President and General Manager of Global ...
Total Annual Compensation: $297.0K
Senior Vice President of Global Product Opera...
Total Annual Compensation: $284.6K
Compensation as of Fiscal Year 2014.

abiomed inc (ABMD) Key Developments

Abiomed Inc. Announces Clinical Trial Results from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP(TM) (Right Percutaneous) System

Abiomed Inc. announced clinical trial results from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP(TM) (Right Percutaneous) System. The clinical trial results demonstrated a survival rate of 73% in the overall patient population. RECOVER RIGHT was an FDA-approved, prospective, multicenter, single arm study designed to evaluate the safety and probable benefit of the Impella RP in patients with right ventricular failure (RVF) refractory to medical treatment and deemed to require hemodynamic support. The 30 patients enrolled in the RECOVER RIGHT trial were categorized into two patient cohorts. Cohort A included patients who developed RVF within 48 hours after implantation of a left ventricular assist device (LVAD). Cohort B examined patients who developed RVF within 48 hours of post-cardiotomy shock or post-acute myocardial infarction (AMI) shock. The primary endpoint was patient survival at 30 days, hospital discharge, or bridge to the next therapy. Overall, the survival rate was 73% in the entire population at 30 days. Cohort A showed a survival rate of 83.3% and Cohort B had a 58.3% survival rate at 30 days.

ABIOMED, Inc. Appoints Dr. Eric Rose as a Class II Director

ABIOMED, Inc. announced that on August 13, 2014, company's board of directors appointed Dr. Eric Rose as a Class II Director, to serve for a term expiring at next annual meeting of stockholders. To accommodate Dr. Rose's appointment, the size of Board of Directors was increased from seven to eight directors. Dr. Rose previously served as a member of company's Board of Directors from May 2007 to January 2012 and has served as a consultant to the company since January 2012.

ABIOMED, Inc. Reports Unaudited Consolidated Financial Results for the First Quarter Ended June 30, 2014; Reiterates Financial Guidance for Fiscal 2015

ABIOMED, Inc. reported unaudited consolidated financial results for the first quarter ended June 30, 2014. The company reported first quarter fiscal 2015 revenue of $48.8 million, an increase of 14% compared to revenue of $42.7 million for the same period of fiscal 2014. First quarter fiscal 2015 GAAP net loss was $1.7 million or a loss of $0.04 per diluted share, compared to GAAP net loss of $1.7 million or $0.04 per diluted share for the prior year period. Loss from operations for the first quarter of fiscal 2015 was $1.5 million, compared to a loss of $1.3 million in the prior year period. The company continues to have no debt and a U.S. federal net operating loss carry-forward of approximately $193 million as of June 30, 2014. Loss before income tax provision was $1.48 million against $1.31 million for the same period of last year. The company reiterates its fiscal year 2015 guidance and expects its total revenues to be in the range of $205 million to $212 million. Largely to incorporate the acquisition of ECP, the company is revising its fiscal year 2015 guidance for GAAP operating margin and now expects it to be in the range of 1% - 4%, compared to the previous guidance of 5% - 7%.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABMD:US $25.18 USD +0.33

ABMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $15.07 USD +0.04
LeMaitre Vascular Inc $6.89 USD -0.10
Spectranetics Corp/The $27.87 USD -0.24
Thoratec Corp $26.15 USD -0.13
Volcano Corp $11.66 USD +0.13
View Industry Companies

Industry Analysis


Industry Average

Valuation ABMD Industry Range
Price/Earnings 100.0x
Price/Sales 5.2x
Price/Book 5.8x
Price/Cash Flow 135.5x
TEV/Sales 4.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABIOMED INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at